Scrip’s senior editor Vibha Ravi speaks with Dr Thomas Rademacher, Emergex CEO and ex-research director at the University of Oxford, about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. Novel delivery mechanisms like patches and microneedles are part of the UK-based clinical-stage biotech’s plan to make universal coronavirus and influenza vaccines affordable and effective as it seeks to partner governments.
https://scrip.pharmaintelligence.informa.com/SC148976/Emergex-CEO-Questions-mRNA-Vaccines-Against-Wuhan-Virus-Works-On-Universal-Vaccines

Ver todos los episodios